KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Preferred Stock Liabilities (2018 - 2019)

Historic Preferred Stock Liabilities for Adaptive Biotechnologies (ADPT) over the last 2 years, with Q2 2019 value amounting to $561.9 million.

  • Adaptive Biotechnologies' Preferred Stock Liabilities changed N/A to $561.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $561.9 million, marking a year-over-year change of. This contributed to the annual value of $560.9 million for FY2018, which is N/A changed from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Preferred Stock Liabilities of $561.9 million as of Q2 2019.
  • Over the past 5 years, Adaptive Biotechnologies' Preferred Stock Liabilities peaked at $561.9 million during Q2 2019, and registered a low of $560.9 million during Q4 2018.